Affluent Medical presents its operational advances

French company Affluent Medical, specializing in innovative medical technologies, recently reported on its significant progress during the "Actu Bourse" program on Boursorama. Michel Therin, Chairman of the Board of Directors, and Sébastien Ladet, CEO, announced a strategic partnership with Edwards Lifesciences for the Epygon valve.

The FDA has given positive feedback on the Kalios adjustable mitral ring, allowing its advancement without the inclusion of new patients. The design of the Epygon valve has been validated and its clinical study is expanding to 11 active centers. The pilot clinical trial for the Artus urinary sphincter is progressing with five patients implanted and the goal of ten before the end of the year.

Affluent Medical also secured €1.1 million in non-dilutive funding for the development of Epygon. Financial analysts have revised the stock price target upwards to €4.04, reflecting increased confidence in the company's prospects.